Glaukos (GKOS)
(Delayed Data from NYSE)
$121.09 USD
-2.15 (-1.74%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $121.08 -0.01 (-0.01%) 5:58 PM ET
2-Buy of 5 2
D Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$121.09 USD
-2.15 (-1.74%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $121.08 -0.01 (-0.01%) 5:58 PM ET
2-Buy of 5 2
D Value F Growth A Momentum F VGM
Zacks News
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
The Zacks Analyst Blog Highlights Globus Medical, Glaukos, PROCEPT, Edwards Lifesciences and Quest Diagnostics
by Zacks Equity Research
Globus Medical, Glaukos, PROCEPT, Edwards Lifesciences and Quest Diagnostics are included in this Analyst Blog.
What's in Store for West Pharmaceutical (WST) in Q4 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) fourth-quarter 2023 results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.
3 Medtech Stocks Likely to Top Estimates This Earnings Season
by Urmimala Biswas
Here are three stocks, GMED, GKOS and PRCT, which are expected to beat earnings estimates in the ongoing reporting cycle.
Glaukos (GKOS) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Glaukos' (GKOS) Preliminary Q4 Revenues Ride on Product Demand
by Zacks Equity Research
Glaukos' (GKOS) revenues in the fourth quarter have been primarily driven by the continued demand for existing and newly launched products.
Glaukos' (GKOS) iDose TR Gets FDA Nod for Glaucoma Treatment
by Zacks Equity Research
The FDA approval of Glaukos' (GKOS) iDose TR is likely to reshape glaucoma care. A micro-invasive breakthrough promises proactive, durable treatment, heralding a new era in eye health.
Glaukos (GKOS) Hits 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Why Is Glaukos (GKOS) Down 0.4% Since Last Earnings Report?
by Zacks Equity Research
Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Glaukos (GKOS) Q3 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Glaukos' (GKOS) third-quarter revenues beat estimates but fall year over year. Sales and gross margin improve, while higher operating expenses lead to a wider operating loss.
Glaukos (GKOS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Glaukos (GKOS) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Medical Device Stocks to Watch for Earnings on Nov 1: MCK & More
by Indrajit Bandyopadhyay
Medical Device companies' Q3 results are likely to reflect strength in customer demand. Let's see how MCK, QDEL, GKOS and NARI are placed ahead of their earnings release.
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Glaukos (GKOS) Q2 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Glaukos' (GKOS) second-quarter revenues beat estimates but fall year over year. Sales and gross margin improve, while higher operating expenses lead to a wider operating loss.
Compared to Estimates, Glaukos (GKOS) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Glaukos (GKOS) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Glaukos (GKOS) delivered earnings and revenue surprises of 3.51% and 7.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Medical Device Aug 2 Earnings Roster: MCK, FMS & GKOS
by Indrajit Bandyopadhyay
Medical Device players are expected to have benefited from the reopening of economies and several efforts to combat staffing challenges. Let's see how MCK, FMS and GKOS are likely to have performed this time.
OrthoPediatrics (KIDS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
OrthoPediatrics (KIDS) delivered earnings and revenue surprises of 0% and 1.16%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Glaukos' (GKOS) New Tie-Up to Address Chronic Eye Disease
by Zacks Equity Research
Glaukos' (GKOS) new partnership is expected to advance next-generation wearable patient engagement and diagnostic technology, thereby making the detection of eye diseases more efficient.